Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
Life Science Institute Begins Muse Cell Trial for Spinal Injury; President Confident of Profitability
To read the full story
Related Article
- Life Science Institute to Establish New Field of Reparative Medicine with Muse Cells: President
May 20, 2021
- Life Science Institute to Begin Exploratory Study of Muse Cell Therapy for COVID-19-Associated ARDS
April 21, 2021
- Life Science Institute to Test Muse Cell Therapy in ALS
January 29, 2021
- Life Science Institute’s Muse Cell Therapy Effective in Epidermolysis Bullosa
July 30, 2020
- Life Science Institute’s Muse Cell Product Shows Safety, Tolerability in 2 Trials
April 24, 2020
- Life Science Institute’s Muse Cell Product Processing Facility Bags Manufacturing License
August 8, 2019
- Life Science Institute Initiates Exploratory Clinical Trial of Muse Cell Product for Epidermolysis Bullosa
December 21, 2018
- Life Science Institute to Initiate Exploratory Clinical Study of Muse Cell Product for Cerebral Infarction
September 4, 2018
- Life Science Institute Launches Clinical Study of IV Regenerative Medicine Product for Acute Myocardial Infarction
January 18, 2018
BUSINESS
- Astellas’ FY2023 Operating Profit Tumbles 80% Due to Iveric Bio Buyout
April 26, 2024
- Daiichi Sankyo Ups FY2025 Sales Goal to 2.1 Trillion Yen on Bullish Cancer Biz
April 26, 2024
- Ono Ties Up with PRISM BioLab in Oncology Drug Discovery
April 26, 2024
- Argenx Seeks Label Expansion for Vyvdura in Japan
April 26, 2024
- Janssen Files Tremfya for Ulcerative Colitis in Japan
April 26, 2024
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…